目的 观察附子人参有效组分不同比例配伍对阿霉素（ADR）诱导的慢性心力衰竭大鼠血流动力学的影响，探讨其对心力衰竭的保护机制。方法 采用腹腔注射ADR方法建立慢性心力衰竭大鼠模型。附子人参有效组分按2∶1，1∶1，1∶2每天灌胃，末次给药后，用16导生理记录仪记录血流动力学指标；称重法检测心肌肥厚指数；ELISA法检测大鼠血浆血管紧张素Ⅱ（AngⅡ）和血管紧张素Ⅱ受体1（At1）含量；实时荧光定量PCR（RT-PCR）法检测心肌组织中At1 mRNA的表达。结果 与模型组比较，附子人参有效组分配伍各组均可明显改善ADR所致的慢性心衰大鼠的血流动力学异常；附子人参2∶1组可明显降低ADR诱导的慢性心衰大鼠心肌肥厚指数的异常升高；也可显著改善慢性心衰大鼠血浆AngⅡ和At1的异常升高，而且能显著升高心肌中At1 mRNA的表达。结论 附子人参有效组分2∶1配伍可能通过拮抗神经内分泌系统的过度激活，抑制心肌肥厚，从而阻断心肌重构，达到改善ADR所致的慢性心力衰竭的作用。

Objective To study the effect of active fraction of Radix Aconiti Lateralis Preparata（Fuzi） and Radix Ginseng（Renshen） on hemodynamics of rat chronic heart failure（CHF） induced by adriamycin（ADR） and to discuss its protective mechanism，thus to provide a reliable basis for clinical application. Methods The rat model of CHF was induced by peritoneal injection of ADR. The model rat was intragastrically given the active fraction of Fuzi-Renshen at the proportions of 2∶1，1∶1，1∶2，respectively. After the last administration，we observed the changes in hemodynamic parameters by 16-lead electrophysiolograph，and weight method was used to detect myocardial Fuzi-Ren shen hypertrophy index. Enzyme-linked immunosorbent assay（ELISA） was applied to examine rat plasma vascular angiotensin Ⅱ（Ang Ⅱ） and angiotensin Ⅱ type 1 receptor（At1） content，real-time fluorescence quantitative PCR（RT-PCR） was used to detect mRNA expression of At1 in myocardial tissue. Results Compared with the model group，Fuzi-Renshen 2∶1，1∶1 and 1∶2 group，could significantly improve the abnormal hemodynamics of CHF rats， 2∶1 group could significantly reduce ADR-induced myocardial hypertrophy index，improve the abnormal rise of plasma Ang Ⅱ and At1 in CHF rats，and increase the mRNA expression of At1 in myocardium. Conclusion Effect fraction of Fuzi-Renshen at the proportions of 2∶1 has therapeutic effect on ADR-induced CHF through resisting the excessive activation of neuroendocrine system，inhibiting cardiac hypertrophy，thereby blocking myocardial remodeling.

R285.5

国家自然科学基金（81173597）；教育部博士点基金（20102227110002）；吉林省医药产业发展专项（YYZX201265）。